Table 1.
Demographic and clinical characteristics of the participants (N = 150).
| Parameters | Groups | ||||
|---|---|---|---|---|---|
| Control group | Type 1 diabetic patients | Type 1 diabetic patients with COVID-19 | Test value | p value | |
| N | 50 | 50 | 50 | — | — |
| Age (years) | 36.08 ± 4.46 | 36.18 ± 3.52 | 36.71 ± 6.63 | 0.222 | 0.801 |
| Gender | |||||
| Male | 15 (30.6%) | 24 (49%) | 26 (51%) | 5.037 | 0.081 |
| Female | 35 (69.4%) | 26 (51%) | 24 (49%) | ||
| T1DM duration (years) | NA | 14.53 ± .96 | 14.75 ± 3.03 | 0.043 | 0.672 |
| Diabetic complications | |||||
| Yes | NA | 20 (40.8%) | 21 (42.9%) | 0.042 | 0.838 |
| None | 30 (59.2%) | 29 (57.1%) | |||
| Comorbidities# | |||||
| Yes | NA | 18 (36.7%) | 31 (61.2%) | 5.880 | 0.015 |
| None | 32 (63.3%) | 19 (38.8%) | |||
| Taking hydroxychloroquine | |||||
| Yes | NA | 13 (26.5%) | 0 (0%) | 22.609 | <0.001 |
| No | NA | 37 (73.5%) | 50 (100%) | ||
Results are summarized as mean ± SD and N (%). #Comorbidities, like hypertension, dyslipidemia, asthma, and iron deficiency anemia. N: number of participants; TIDM: type 1 diabetes mellitus; NA: not applicable. p < 0.05 is considered significant.